Phase-I study MEDI-534, of a live, attenuated intranasal vaccine against respiratory syncytial virus and parainfluenza-3 virus in seropositive children.
A live, attenuated respiratory syncytial virus and parainfluenza virus type 3 vaccine was evaluated in healthy respiratory syncytial virus/parainfluenza virus type 3 seropositive children aged 1 to 9 years. Three cohorts of 40 children were randomized 1:1 to receive 10, 10, or 10 median tissue culture infectious dose50 MEDI-534 vaccine or placebo. The vaccine's safety profile was similar to placebo, no viral shedding was detected, and the vaccine was minimally immunogenic.
Gomez
Margarita
M
MedImmune, Gaithersburg, MD 20878, USA.
Mufson
Maurice A
MA
Dubovsky
Filip
F
Knightly
Conor
C
Zeng
Wen
W
Losonsky
Genevieve
G
D000281:Administration, Intranasal; D002648:Child; D002675:Child, Preschool; D005243:Feces / Q000821:virology; D005260:Female; D006805:Human Experimentation; D006801:Humans; D007223:Infant; D008297:Male; D022241:Parainfluenza Vaccines / Q000008:administration & dosage / Q000009:adverse effects / Q000276:immunology*; D010224:Parainfluenza Virus 3, Human / Q000276:immunology*; D018184:Paramyxoviridae Infections / Q000517:prevention & control*; D010919:Placebos / Q000008:administration & dosage; D018357:Respiratory Syncytial Virus Infections / Q000517:prevention & control*; D022261:Respiratory Syncytial Virus Vaccines / Q000008:administration & dosage / Q000009:adverse effects / Q000276:immunology*; D012136:Respiratory Syncytial Viruses / Q000276:immunology*; D014613:Vaccines, Attenuated / Q000008:administration & dosage / Q000009:adverse effects / Q000276:immunology; D017201:Virus Shedding
D022241:Parainfluenza Vaccines; D010919:Placebos; D022261:Respiratory Syncytial Virus Vaccines; D014613:Vaccines, Attenuated